Increased use of higher-cost medicines continues to put pressure on Canadian public drug plans

Imported from official source

Announcement

Safety Classified by Officially

A new Patented Medicine Prices Review Board (PMPRB) report finds that prescription drug expenditures by Canadian public drug plans increased by 4.2% in 2020-21, bringing annual spending to $12.3 billion.

January 31, 2023 — Ottawa, ON — Patented Medicine Prices Review Board

A new Patented Medicine Prices Review Board (PMPRB) report finds that prescription drug expenditures by Canadian public drug plans increased by 4.2% in 2020-21, bringing annual spending to $12.3 billion. The use of higher-cost medicines has been the primary factor behind rising costs for the public plans over the past five years, and this pressure continues to build.

In 2020-21, high-cost drugs accounted for over one third of total drug costs and yet were only used by 2.5% of drug plan beneficiaries. The 10 highest-cost drugs reimbursed by the public drug plans were all rare disease treatments with annual treatment costs of over $200,000.

These findings were released today by the PMPRB in the eighth edition of CompassRx, an annual report published under the National Prescription Drug Utilization Information System (NPDUIS) research initiative. CompassRx provides insight into the factors driving prescription drug expenditures in select Canadian public drug plans. This edition focuses on the 2020-21 fiscal year.

The study includes all provincial public drug plans (with the exception of Quebec), as well as Yukon and the Non-Insured Health Benefits Program. These plans account for approximately one third of the total annual spending on prescription drugs in Canada. 

Prescription drug expenditures for the NPDUIS public drug plans grew by 4.2% in 2020/21, following a 3.7% increase in 2019/20.

Between 2015/16 and 2020/21, the total prescription drug expenditures for Canada’s public drug plans rose by $2.5 billion, for a compound annual growth rate of 5.6%.

This is an extract. The publication continues at the source.

Source: Patented Medicine Prices Review Board. Licence

Read the original at the source: https://www.canada.ca/en/patented-medicine-prices-review/news/2023/01/increased-use-of-higher-cost-medicines-continues-to-put-pressure-on-canadian-public-drug-plans.html

Officially imported this from Patented Medicine Prices Review Board’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.

Provenance

Organization
Patented Medicine Prices Review Board — imported from official source
Official source
https://api.io.canada.ca/io-server/gc/news/en/v2?dept=patentedmedicinepricesreviewboard&sort=publishedDate&orderBy=desc&publishedDate%3E=2021-07-23&pick=50&format=atom&atomtitle=Patented%20Medicine%20Prices%20Review%20Board ATOM
Imported
October 03, 2026 20:43
Versions
1 recorded
Identity
https://www.canada.ca/en/patented-medicine-prices-review/news/2023/01/increased-use-of-...

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.